This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ritalin LA

Novartis AG

Drug Names(s): methylphenidate hydrochloride extended release

Description: Ritalin LA is a once-daily formulation of Ritalin, Novartis' previously approved ADHD treatment. This once-daily capsule provides all day treatment with one morning dose, unlike most ADHD treatments that require a midday dose. This dosing regimen eliminates the social stigma issues felt by children having to bring medication to school and decreases the possibility of medication misuse.

Ritalin LA uses the propriety SODAS (Spheroidal Oral Drug Absorption System) technology. Each bead-filled Ritalin LA capsule contains half the dose as immediate-release beads and half as enteric-coated, delayed-release bears, thus providing an immediate release or methylphenidate and a second delayed release of methylphenidate.

Ritalin LA is a central nervous system stimulant. The exact mechanism of action in ADHD is unknown. The drug is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.

Deal Structure: Ritalin LA was developed by Elan Corporation, plc's drug delivery division and will be supplied to Novartis under an exclusive worldwide royalty and manufacturing agreement between the companies. Novartis Pharmaceuticals Corporation has commercialization rights for Ritalin LA in the U.S.

Celgene entered into an agreement with Novartis in April 2000 and receives royalties on all of Novartis' Ritalin family of ADHD-related products.

Elan and Alkermes
In May 2011, Alkermes and Elan announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies (EDT), the drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million. Alkermes and EDT will be combined under a new holding company incorporated in Ireland. This newly created company will be named Alkermes plc. In September 2011, Alkermes and Elan announced the completion of the merger.

Partners: Celgene Corporation Alkermes plc

Ritalin LA News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug